With the business potentially at an important milestone, we thought we'd take a closer look at Ekso Bionics Holdings, Inc.'s (NASDAQ:EKSO) future prospects. Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The US$14m market-cap company’s loss lessened since it announced a US$15m loss in the full financial year, compared to the latest trailing-twelve-month loss of US$11m, as it approaches breakeven. Many investors are wondering about the rate at which Ekso Bionics Holdings will turn a profit, with the big question being “when will the company breakeven?” Below we will provide a high-level summary of the industry analysts’ expectations for the company.

View our latest analysis for Ekso Bionics Holdings

According to the 2 industry analysts covering Ekso Bionics Holdings, the consensus is that breakeven is near. They expect the company to post a final loss in 2026, before turning a profit of US$5.4m in 2027. The company is therefore projected to breakeven around 2 years from now. What rate will the company have to grow year-on-year in order to breakeven on this date? Using a line of best fit, we calculated an average annual growth rate of 59%, which is extremely buoyant. If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict.

Underlying developments driving Ekso Bionics Holdings' growth isn’t the focus of this broad overview, though, bear in mind that generally a high forecast growth rate is not unusual for a company that is currently undergoing an investment period.

One thing we’d like to point out is that The company has managed its capital prudently, with debt making up 36% of equity. This means that it has predominantly funded its operations from equity capital, and its low debt obligation reduces the risk around investing in the loss-making company.

Next Steps:

There are too many aspects of Ekso Bionics Holdings to cover in one brief article, but the key fundamentals for the company can all be found in one place – Ekso Bionics Holdings' company page on Simply Wall St. We've also compiled a list of essential factors you should further research:

1. Historical Track Record: What has Ekso Bionics Holdings' performance been like over the past? Go into more detail in the past track record analysis and take a look at the free visual representations of our analysis for more clarity.
2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Ekso Bionics Holdings' board and the CEO’s background.
3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.